Value of PET/MRI for assessing tumor resectability in NSCLC - intra-individual comparison with PET/CT
Michael Messerli, Felipe Barbosa, Magda Marcon, Urs J Muehlematter, Paul Stolzmann, Rene Warschkow, Gaspar Delso, Edwin Egw Ter Voert, Martin W Huellner, Thomas Frauenfelder & Patrick Veit-Heibach
In NSCLC the use of PET/MRI, including a dedicated pulmonary MR imaging protocol, provides a comparable diagnostic value for determination of tumor resectability compared to PET/CT. Advances in knowledge: Our findings suggest that whole body PET/MRI can safely be used for the local staging of NSCLC patients. Further studies are warranted to determine whether it is feasible to integrate an imaging sequence in a whole body PET/MRI setting with the potential advantage of detection of liver or brain metastases.
|citation||Messerli M, Barbosa F, Marcon M, Muehlematter U J, Stolzmann P, Warschkow R, Delso G, Ter Voert E E, Huellner M W, Frauenfelder T, Veit-Heibach P. Value of PET/MRI for assessing tumor resectability in NSCLC - intra-individual comparison with PET/CT. Br J Radiol 2018;20180379.|
|type||journal paper/review (English)|
|date of publishing||13-09-2018|
|journal title||Br J Radiol|